Your session is about to expire
← Back to Search
ADXS-503 for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new cancer treatment, ADXS-503, alone and in combination with another cancer treatment, pembrolizumab, in people with metastatic squamous or non-squamous non-small cell lung cancer.
- Non-Small Cell Lung Cancer
- Non-Squamous Carcinoma
- Squamous Cell Carcinoma
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many healthcare facilities are currently administering this trial?
"Nine healthcare centres are collaborating on this clinical trial, such as Atlantic Health System, the Carol G Simon Cancer Center in Morristown and Virginia Cancer Specialists in Fairfax. In addition to these 3 sites there are 6 other locations conducting trials including Providence Cancer Institute in Portland."
How many participants are currently involved in this clinical research?
"To facilitate the trial's progress, 74 qualified participants are needed. The sponsor of this research is Advaxis, Inc., and it will be conducted in various locations such as Atlantic Health System, Carol G Simon Cancer Center located in Morristown (NJ) and Virginia Cancer Specialists based on Fairfax (VA)."
To what ailments is ADXS-503 typically prescribed?
"ADXS-503 has been approved for usage in treating malignant neoplasms and can also be used to address the challenges posed by unresectable melanoma, microsatellite instability high, or a lack of response from chemotherapy."
What prior investigations have been conducted on ADXS-503?
"ADXS-503 was initially studied at City of Hope in the year 2010. Currently, there are 251 completed studies and 961 ongoing investigations, with a number of them located in Morristown, New jersey."
Is enrollment currently being offered for this research project?
"Affirmative. The clinical trial details hosted on clinicaltrials.gov indicate that the experiment, which was initially posted in February of 2019, requires 74 participants from 9 separate centres and is currently seeking out candidates."
What outcomes is this trial seeking to accomplish?
"This 4-year trial aims to evaluate the Saftey/Tolerability of ADXS-503 monotherapy in Part A and ADXS-503 with pembrolizumab in Part B according to CTCAE termionology criteria. Secondary objectives involve measuring preliminary anti-tumor activity, overall survival (OS) rates for subjects treated with either drug alone or both drugs together, as well as safety measures such as adverse events and dose limiting toxicities graded per CTCAE version 4.03."
Share this study with friends
Copy Link
Messenger